Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Senior writer
Maryland, USA
15+ years of experience
Scrip
By Joseph Haas 27 Nov 2020
The pharma and the Google spinout focused on aging are adding $1bn in funding to their 2014 collaboration, which has yielded more than two dozen preclinical candidates so far.
Topic Alzheimer's Disease
Pink Sheet
By Joseph Haas 29 Oct 2020
EUA request for COVID-19 vaccine is unlikely before late November; the CEO’s frequent comments that the timetable isn’t politically motivated are unusual to say the least
Scrip
By Joseph Haas 01 May 2020
With efficacy data in hand, Gilead wants to balance economic sustainability with broad availability of remdesivir for COVID-19 patients. The firm did not alter guidance on Q1 earnings call.
Scrip
By Joseph Haas 20 Apr 2020
Big pharma stocks, with few exceptions, saw big declines in valuation in the quarter amid the COVID-19 stock market rollercoaster, but pharma outperformed the S&P 500, showing the industry's resiliency in a global health crisis.
Scrip
By Joseph Haas 15 Jan 2020
Biktarvy’s powerful sales growth and the potential of a first-in-class capsid inhibitor in both prevention and heavily treatment-experienced patients are key to Gilead’s plan for staying on top in HIV.
Topic Business Strategies Infectious Diseases Life Cycle Management
Datamonitor Healthcare
By Joseph Haas 04 Nov 2019
Non-alcoholic steatohepatitis (NASH) is poised to become an even greater epidemic and pharma companies of all sizes are competing to be the first to bring a NASH drug to market. Listen to an in-depth discussion about new and repurposed drug exploration treat NASH, as well as deal making, licensing and partnerships activity for the area.
Topic Cell & Gene Therapy Drug Development Landscape Approvals
Scrip
By Joseph Haas 11 Sep 2019
The Medicines Co. unveiled Phase III safety data for inclisiran showing safety and tolerability comparable to placebo and efficacy in line with the PCSK9 inhibitor class – which should be the reassurance it needs for the oral agent.
Scrip
By Joseph Haas 03 Jul 2019
Looking back at the second quarter, PharmaVitae analysts have selected 10 biopharma companies with market caps under $3bn they think are primed for acquisition – and the likely candidates for a buy-out.
Scrip
By Joseph Haas 12 Sep 2018
A review of tech transfer deals over 10 years shows that licensees often protect their value positions to limit royalties paid out to licensors. Meanwhile, licensors often protect their future rights with language recognizing that additional parties may be involved in producing a final product.
Topic Digital Health
Scrip
By Joseph Haas 30 Aug 2018
Offering better efficacy than Shire’s existing HAE therapies and dosing convenience compared to CSL Behring’s prophylactic Haegarda, the specialty pharma may take back market share lost to its competitor and consolidate its leadership in the space.
Topic FDA
Scrip
By Joseph Haas 14 Jun 2018
Having previously criticized the biopharma industry for squandering the benefits of US tax reform, the former Teva CEO called for more M&A deals that offer a clear strategic rationale, pointing to Takeda/Shire as an example.
Topic BioPharmaceutical
Pink Sheet
By Joseph Haas 06 Jun 2018
Former Teva and current Ovid CEO Jeremy Levin says pharma should use tax reform gains for business development, not share buybacks. Also, Patient-focused drug development (PFDD) is about more than just getting new drugs approved, an advocate says, while FDA previews coming guidance on PFDD. And, Alnylam’s CEO reflects on what it took financially to get RNAi to the threshold of its first product approval.
Scrip
By Joseph Haas 19 Jan 2018
Shire is pushing Xiidra hard to take market share away from Allergan's well established Restasis, but the pending arrival of a generic Restasis throws a curveball into the whole category.
Topic Business Strategies
Scrip
By Joseph Haas 18 Jan 2018
While Mustang was acquiring CAR-T intellectual property from Harvard and Juno licensed gamma-secretase inhibitor.
Pink Sheet
By Joseph Haas 18 Jan 2018
Longitudinal observational study of NASH patients provides data to companies to help them better understand disease.
Topic Clinical Trials
Scrip
22 Jul 2022
Scrip
05 Jul 2022
Scrip
01 Jul 2022
Scrip
28 Jun 2022
Scrip
24 Jun 2022
Scrip
23 Jun 2022
Scrip
17 Jun 2022
Scrip
16 Jun 2022
Scrip
10 Jun 2022
Scrip
07 Jun 2022
Scrip
06 Jun 2022
Scrip
03 Jun 2022
Scrip
02 Jun 2022
Scrip
31 May 2022
Scrip
27 May 2022
